Fig. 5

Soluble and oligomeric tau levels in JNPL3 mice. a, b, c, d JNPL3 mice were injected at 3 months of age and sacrificed 4 months post-injection. Levels of total and phosphorylated tau (pThr231, pSer202, pSer396/404) were tested on heat stable preparations (hsp) from 3 different brain regions, using low-tau ELISA: (a) cortex (ctx), (b) hindbrain (HB) and (c) hippocampus. Soluble tau was mostly unchanged in all brain areas in the AAV1-CAG-scFvMC1group (scFvMC1) (n = 13) compared to the AAV1-CAG-eGFP injected cohort (Controls) (n = 13). Two different phosphorylation sites, pSer202 (CP13 antibody, early site) and pSer396/404 (PHF1 antibody, late site) were increased in the scFvMC1 treated group (*p < 0.05, **p < 0.01, non parametric Mann-Whitney test). (d) Oligomeric/aggregated tau was measured using the DA9/DA9 mono-ELISA showing no modulation in any of the brain areas analyzed (cortex, ctx; hindbrain, HB; hippocampus). Controls are the AAV1-CAG-eGFP injected mice (n = 13); scFvMC1 corresponds to the AAV1-CAG-scFvMC1 group (n = 13). Graphs are expressed as % Control, and means +/− SEM